← Back to Search

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

Phase 4
Waitlist Available
Led By Martin Taylor, DO, PHD
Research Sponsored by The Orthopedic Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing Ingrezza, a medication that may help people with cervical dystonia, a condition causing involuntary neck movements. The study will last a few months and involve periodic check-ups. The medication works by balancing brain chemicals to improve muscle control.

Eligible Conditions
  • Torticollis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in incidence of pain/spasm

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: IngrezzaExperimental Treatment1 Intervention
Participants will receive Ingrezza orally once daily for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ingrezza Pill
2021
Completed Phase 4
~20

Find a Location

Who is running the clinical trial?

The Orthopedic FoundationLead Sponsor
Martin Taylor, DO, PHDPrincipal Investigatorprinciple investigator
~5 spots leftby Dec 2025